Does Urolithin A Build Muscle? What the (Missed) Trial Endpoints Actually Show

TL;DR

• Two different bars of evidence - "upregulates mitophagy" is a cellular housekeeping claim with decent support; "makes you measurably stronger" needs a powered trial with a pre-declared primary endpoint.
• The most-cited trial missed its primary endpoint - peak power output did not separate from placebo in the 2022 Cell Reports Medicine study in middle-aged adults.
• The widely quoted ~12% strength figure was a secondary/exploratory signal, not the hypothesis the trial was built to test.
• A separate RCT in older adults missed both co-primaries - six-minute walk distance and maximal muscle ATP production - while some muscle-endurance measures did improve.
• The pivotal trials were largely manufacturer-funded, which is a reason for extra scrutiny of design, publication and framing rather than less.
• Only roughly a third to 40% of people carry the gut bacteria needed to convert dietary ellagitannins into meaningful urolithin A - the honest rationale for taking it directly.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed. Urolithin A is a dietary supplement, not an approved treatment for any condition.

---

The pitch vs the data

The consumer pitch for urolithin A is compact and appealing: it helps your cells recycle old, damaged mitochondria, so your muscles get a fresher population of energy factories, so you get stronger and more powerful. Each arrow in that chain sounds reasonable. Together they make a much bigger leap than they sound.

"Recycles old mitochondria" is a cellular housekeeping claim, and it has decent support. "Therefore builds muscle and makes you measurably stronger" is a whole-body functional claim - the kind that has to survive a properly powered randomized controlled trial with a pre-declared primary endpoint. Those are two very different bars of evidence. A molecule can clear the first and still fail the second, and that is roughly where urolithin A sits today.

This article is not about the mechanism - our companion piece on urolithin A and mitophagy covers how the recycling pathway is thought to work. Here we are asking the narrower, more practical question a prospective user actually cares about: per the trials, does it make you stronger, and how good is that evidence?

What urolithin A has going for it

Two things deserve honest credit before the critique.

Mitophagy is a real, measurable pathway. In preclinical models and in human biomarker data, urolithin A does appear to upregulate the removal of dysfunctional mitochondria and shift markers of mitochondrial health. That is not fringe science; it is why serious longevity researchers pay attention to the molecule at all. We treat the mechanism in depth in the mitophagy sibling article.

The gut-conversion problem gives direct supplementation a rationale. Urolithin A is not something most foods contain. Your body normally makes it in the gut by converting ellagitannins - compounds in pomegranate, walnuts, and some berries - using specific gut bacteria. The catch is that only roughly a third to 40% of people carry the microbiome needed to produce meaningful amounts. Eat the same pomegranate, and a "non-producer" simply won't generate much urolithin A. That population gap is the honest case for taking it directly rather than relying on diet: it standardizes exposure across people who would otherwise get little to none.

So the setup is legitimate. The question is whether legitimate mechanism plus standardized exposure actually translates into the outcome people are buying it for.

The muscle trials, read honestly

The most cited human trial is Singh and colleagues, published in Cell Reports Medicine in 2022. It was a randomized, placebo-controlled study in middle-aged adults over about four months, using the branded urolithin A ingredient (Mitopure), and it was funded by the manufacturer (Amazentis / Timeline). This is the study most "urolithin A builds muscle" headlines trace back to.

Here is the part the headlines usually skip: the trial did not meet its primary endpoint. The pre-specified primary outcome was a measure of muscle power (peak power output), and on that measure urolithin A did not separate significantly from placebo. The widely-quoted "~12% improvement in muscle strength" was a secondary/exploratory signal - a genuine and interesting result, but not the primary hypothesis the trial was built to test, and secondary findings carry less evidentiary weight because they are more prone to chance when many measures are examined.

A separate randomized trial in older adults (published in JAMA Network Open) followed a similar pattern: its co-primary endpoints - six-minute walk distance and maximal muscle ATP production - did not significantly beat placebo, while some muscle-endurance measures did improve.

So across the pivotal, largely manufacturer-funded muscle trials, the recurring shape is consistent:

• Mechanistic and mitochondrial-biomarker signals: present.
• Muscle-endurance and aerobic signals: sometimes present, generally modest.
• Hard primary strength, power, or mass endpoints: not convincingly met.

What "missed the primary endpoint" means - and what it doesn't. It does not mean urolithin A does nothing, or that the biomarker findings are fake. It means the specific, pre-committed, most-rigorous test of the flagship claim came back negative. In drug development that is often the difference between "promising" and "proven." A molecule that misses its primary endpoint but posts nice secondary numbers is a signal worth following up - not a finished case for efficacy.

What the trials measured vs what they showed

The table is the whole story in miniature: the molecule looks best on the softer, biomarker-and-endurance end and weakest exactly where the consumer promise is loudest - strength, power, and building muscle.

Where a signal may still exist

None of this is a dismissal. The most defensible read is that urolithin A's real-world value, if any, lives on the mitochondrial-quality and muscle-endurance side rather than the raw strength and hypertrophy side. Fatigue resistance and how efficiently a muscle sustains work are legitimate, quality-of-life-relevant outcomes - they just aren't the same thing as a bigger, stronger muscle.

There is also a real "who benefits most" question the trials haven't fully answered. It is plausible that people starting from a lower baseline - older adults, the sedentary, or the gut-microbiome non-producers who make almost none of their own urolithin A - have more room to respond than a healthy, trained person who already turns their mitochondria over efficiently. That is a reasonable hypothesis, and it is exactly the kind of thing worth measuring in an individual rather than assuming. Establishing your own baseline before adding anything is the logic behind Vivre Labs' V-04 Cellular protocol, which starts from measured mitochondrial and performance markers rather than a generic promise.

Funding, endpoints, and how to read supplement trials

A short, reusable literacy checklist, because it applies well beyond this one molecule:

Who paid for it? Manufacturer-funded trials are not automatically wrong - many are well-run - but funding shapes design, publication, and framing. When the pivotal evidence for an ingredient comes almost entirely from the company selling it, that is a reason for extra scrutiny, not less.

Was the primary endpoint met? This is the single most useful question a non-specialist can ask. Trials declare, in advance, the one or two outcomes they are really testing. If the press release celebrates a secondary number while the primary one quietly failed, you are reading marketing, not proof.

Biomarker or function? A better blood marker or a bump in a cellular readout is mechanistic evidence. Whether you can walk farther, lift more, or fall less is a functional outcome. The gap between the two is where a lot of supplement hype lives.

Effect size and durability. "Statistically significant" is not "noticeable." Ask how big the change was, whether it persisted, and whether it would matter in daily life.

Run urolithin A through that checklist and the verdict is neither hype nor dismissal: real mechanism, mostly manufacturer-funded trials, primary strength endpoints not met, secondary signals worth watching.

Where urolithin A sits vs creatine, protein, and training

The most useful thing to say about urolithin A for muscle is that it is not a substitute for the basics - and, on current evidence, it sits below them.

If the goal is to get stronger or add muscle, the honest hierarchy is unchanged: train, eat enough protein, and - if you want a supplement with a genuinely robust independent evidence base for strength and power - creatine is the one that has earned that reputation. Urolithin A is a plausible mitochondrial-quality play for the right person, layered on top of the basics and ideally monitored. It is not a shortcut, and treating it as one is where the marketing and the data part ways.

Frequently asked questions

Does urolithin A increase strength? Not convincingly, per the primary endpoints of the pivotal trials. The most-cited middle-aged-adult RCT missed its primary muscle-power endpoint, and a strength improvement of around 12% appeared only as a secondary/exploratory signal - encouraging, but not the confirmed result the headlines imply. The stronger case is for muscle endurance and mitochondrial biomarkers, not raw strength.

Is Mitopure proven? "Proven" is too strong. Mitopure is the branded urolithin A used in the key trials, and those trials do show mechanistic and secondary-outcome signals. But the studies are largely manufacturer-funded, and the flagship functional endpoints on strength and power were not met. It is best described as a well-characterized ingredient with promising but incomplete efficacy evidence.

How is it different from NAD boosters? Both target mitochondrial health but by different routes. Urolithin A is aimed at mitophagy - clearing out damaged mitochondria. NAD precursors like NMN and NR aim to raise levels of NAD⁺, a coenzyme central to energy metabolism. They are complementary ideas, and both share the same honest caveat: strong mechanism, human functional data still catching up. See also does NAD decline with age?

Who's most likely to respond? The best hypothesis - not yet firmly proven - is that people with the most room to gain respond most: older or sedentary individuals, and the majority of the population who are gut-microbiome "non-producers" and make little urolithin A on their own. The way to know is to measure your own baseline and re-measure, rather than assume you're a responder.

Related reading

• Urolithin A and mitophagy: how the recycling mechanism works
• NAD, NMN, and NR: the NAD⁺ boosters, honestly
• How to get more energy: the mitochondrial angle
• SS-31 and MOTS-c: the mitochondrial peptides
• Spermidine and autophagy
• Research on what, in whom, measured how - how to read what a study actually measured

Part of The Complete Guide to Mitochondria & Cellular Energy

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore NAD⁺.

---

Urolithin A is a dietary supplement, not an approved treatment for any condition, and nothing here should be read as a promise of a specific result. Individual responses vary, and any use should be physician-directed and, where appropriate, monitored. This article is educational and does not constitute medical advice. Claims for the Malaysian market are subject to MAB requirements.

References

• Singh A, et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 2022 (manufacturer-funded; NCT03464500). Primary endpoint (peak power output) not met; secondary improvements in muscle strength (~12%), aerobic/endurance measures, and mitochondrial biomarkers reported.
• Liu S, et al. "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial." JAMA Network Open, 2022. Co-primary endpoints (six-minute walk distance; maximal ATP production) not significantly different from placebo; muscle-endurance measures improved.
• Timeline / Amazentis published research summaries on Mitopure (manufacturer materials - cited for transparency on funding and framing, not as independent evidence).
• Background reviews on urolithin A gut conversion from dietary ellagitannins and the ~30–40% "producer" prevalence in the general population.